InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
AFT | Ann: Transition to new NZX listing rules wef 1 April 2019 | 18/03/19 | 0 | 334 | |||
|
|||||||
AFT | Ann: AFT Completes Successful Development of Maxigesic Rapid | 01/03/19 | 0 | 101 | |||
|
|||||||
AFT | Ann: 2019 New Year Letter to Investors | 20/02/19 | 0 | 121 | |||
|
|||||||
AFT | Ann: Waiver from NZX Main Board Listing Rule 5.2.3 | 17/12/18 | 0 | 155 | |||
|
|||||||
AFT | Ann: Ongoing Disclosure Notice | 14/12/18 | 0 | 160 | |||
|
|||||||
AFT | Ann: New trial of MAXIGESIC® pain relief published in major int | 03/12/18 | 0 | 179 | |||
|
|||||||
AFT | Ann: narrative correct on page 18 of the Interim Report | 23/11/18 | 0 | 208 | |||
|
|||||||
AFT | Ann: FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2018 | 22/11/18 | 0 | 174 | |||
|
See All Discussions